News | July 21, 2021
Syngene Q1 FY22 revenue grows 41%
The first quarter performance reflects growth across all its business divisions as the company continued to operate at normal levels
The first quarter performance reflects growth across all its business divisions as the company continued to operate at normal levels
The company has reported PAT of Rs. 10.7 crore for Q1 FY22, higher by 23% YoY
The company has already embarked upon significant expansion in Turkey
In addition to supporting the ongoing development of the first IND-approved product in clinical trials, the proceeds will also be used to expand the 3D printed drug product pipeline
The company has now received the renewed GMP (Good Manufacturing Practices) certificate thereby confirming the successful closure of the inspection
The TWYMEEG approval is supported by numerous preclinical and clinical studies, including the Phase 3 TIMES (Trials of IMeglimin for Efficacy and Safety) program managed jointly by both the companies
The end user can validate the authenticity of the product by scanning the digital code with the help of a smartphone letting the end user know it is safe to use
The company recorded revenue of Rs 528crore as compared to Rs 444 crore, registering a growth of 19% over the corresponding quarter ended 31st March 2020
These vaccine doses will be manufactured and stockpiled by the company from August-December 2021
US revenues were sequentially stable at US$370mn with steady performance in the specialty portfolio
Subscribe To Our Newsletter & Stay Updated
